You always hear Cramer shouting about Bristol – Maaah-yerss. Why is that?» Read More
Here's why "Mad Money" host Jim Cramer thinks the market isn't done falling yet.
After news that U.S. missile strikes in Syria could come "as early as Thursday," Cramer suggested some sectors that may help investors protect portfolios amid geopolitical turmoil.
The investment bank highlights eight industry themes it describes as "creative destruction" - trends that make it necessary for companies to either "adapt or die."
In a note to clients, Goldman Sachs strategist David J. Kostin on Wednesday identified what he thinks are the top 40 most undervalued stocks.
Wary of rising rates, stock traders will keep an eye on the bond market Thursday as another wave of earnings reports roll in.
Huge earnings are coming in the week ahead. Companies including Apple, McDonald’s and Boeing all report. Are you ready?
After a two-week hiatus for summer break, Talking Squawk, the official "Squawk Box" blog, is back (lucky you) with all the tidbits, insights and sarcasm you expect.
Pharmaceutical and biotech stocks have outperformed markets this year, and with J&J's second-quarter earnings beat, investors may hope earnings will push stocks even higher.
The delay of Obamacare's employer mandate isn't a blow to health-care stocks. However, the outlook for reform is another matter.
Amgen's low-ball offer to Onyx Pharmaceuticals has set off speculation of a potential bidding war that could leave another company walking away with Onyx.
Independent of the debate on the Federal Reserve and interest rates, FTI Consulting's Barbara Ryan expects pharmaceutical and biotech stocks can continue to do well.
Some of the names on the move ahead of the open.
Cramer has become more cautious on the market right now and conditions are creating a "nightmare scenario" for just about everyone involved, he said on CNBC.
“I’m not crazy about the market,” Cramer said. Now what?
“The price action is confounding more people than I have seen in some time,” said Cramer. What's going on?
Bristol-Myers Squibb and Merck stocks climbed higher Monday as analysts said billions stood to be made from treatment breakthroughs.
Take a look at some of Monday's midday movers:
A dispute within the FDA on whether to put new lung-cancer warnings on ARBs taken by millions of people is unlikely to have any significant effect on the manufacturers stocks.
Several key areas are dangerous for investors in this economic environment, said Jim Cramer, and his charitable trust sold two key stocks.
The spotlight at this year's American Society of Clinical Oncologists meeting will be on data from Bristol-Myers Squibb, Roche, and Merck on a new class of cancer drugs.